scholarly journals A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)

CNS Drugs ◽  
2018 ◽  
Vol 32 (3) ◽  
pp. 289-301 ◽  
Author(s):  
Tim L. Wigal ◽  
Jeffrey H. Newcorn ◽  
Nelson Handal ◽  
Sharon B. Wigal ◽  
Ioulietta Mulligan ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Controlled Release ◽  
Phase Ii ◽  
Attention Deficit ◽  
Phase Ii Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Hyperactivity Disorder ◽  
Dsm 5

scholarly journals Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder

2014 ◽  
pp. 2321 ◽  
Author(s):  
Evelyne Jacqz-Aigrain ◽  
Eric Konofal ◽  
Wei Zhao ◽  
Michel Lecendreux ◽  
Florentia Kaguelidou ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Phase Ii ◽  
Attention Deficit ◽  
Phase Ii Study ◽  
Pilot Phase ◽  
Hyperactivity Disorder

scholarly journals Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial

2019 ◽  
Vol Volume 15 ◽  
pp. 1193-1209 ◽  
Author(s):  
Celestino Rodíguez ◽  
Trinidad Garcia ◽  
Debora Areces ◽  
Estrella Fernández ◽  
Marcelino García-Noriega ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Docosahexaenoic Acid ◽  
Attention Deficit ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Hyperactivity Disorder
Sign in / Sign up

Export Citation Format

Share Document